Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

1,100.00USD
17 Nov 2016
Change (% chg)

-- (--)
Prev Close
$1,100.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22
52-wk High
$1,231.90
52-wk Low
$800.00

Select another date:

Tue, Nov 22 2016

BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin

BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe

* Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe Source text for Eikon: Further company coverage:

UPDATE 1-Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug

* Japan set cut due to high price of drug, Ono confirms (Adds Japan price details)

Roche, Bristol-Myers cut cancer drug prices to win UK approval

LONDON Roche and Bristol-Myers Squibb on Thursday became the latest drugmakers to cut the price of cancer medicines in order to secure access to Britain's National Health Service.

Roche, Bristol-Myers cut cancer drug prices to win UK approval

LONDON, Nov 17 Roche and Bristol-Myers Squibb on Thursday became the latest drugmakers to cut the price of cancer medicines in order to secure access to Britain's National Health Service.

BRIEF-Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration

* Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration focused on microbiome-derived biomarkers,drug targets, bioactive molecules

BRIEF-Opdivo (nivolumab) demonstrates overall survival benefit in patients with unresectable advanced or recurrent gastric cancer in phase 3 study

* Opdivo (nivolumab) demonstrates overall survival benefit in patients with unresectable advanced or recurrent gastric cancer in phase 3 study

BRIEF-Bristol-Myers Squibb and Pfizer to deliver 12 new Eliquis (apixaban) presentations at American Heart Association (AHA) scientific sessions 2016

* Bristol-Myers Squibb and Pfizer to deliver 12 new Eliquis (apixaban) presentations at American Heart Association (AHA) scientific sessions 2016 Source text for Eikon: Further company coverage:

Bristol-Myers' Opdivo succeeds in key stomach cancer study

Bristol-Myers Squibb Co said on Thursday its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.

UPDATE 2-Bristol-Myers' Opdivo succeeds in key stomach cancer study

Nov 10 Bristol-Myers Squibb Co said on Thursday its blockbuster immunotherapy Opdivo helped patients with advanced stomach cancer live longer in a late-stage study, becoming the first drug of its kind to show a survival benefit in these patients.

Select another date: